Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
More News related to NKTR
- Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
- Nektar Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
- Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
Morgan Joseph reiterates a 'Buy' on Nektar Therapeutics (Nasdaq: NKTR), price target $12.
Morgan analyst says, "While Nektar Therapeutics continues to be stigmatized by the failure of its inhaled insulin program a few years ago, its PEG technology and pipeline are orchestrating a strong comeback, in our opinion. Since Howard Robin joined Nektar in 2007, the company has gone through a substantial transformation and is focused on monetizing its superior PEG technology platform. The recently announced lucrative partnership with AstraZeneca could be a harbinger of future deals for Nektar's pipeline drugs. NKTR-102, a pegylated version of irinotecan, is currently in mid-stage trials, and could be the company's next partnership candidate."
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
Related Categories
Analyst CommentsStocks Mentioned
-0.31Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
